Literature DB >> 19075059

Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.

Holly Kimko1, Bindu Murthy, Xu Xu, Partha Nandy, Richard Strauss, Gary J Noel.   

Abstract

Population pharmacokinetic analysis demonstrated that renal function, as assessed by creatinine clearance (CL(CR)), was the patient characteristic that had a clinically relevant impact on ceftobiprole pharmacodynamics. Dosing adjustments based on CL(CR) for subjects with renal impairment should provide ceftobiprole exposure similar to that in patients with normal renal function.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19075059      PMCID： PMC2650522          DOI： 10.1128/AAC.00632-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Authors:  Gary J Noel; Richard S Strauss; Karen Amsler; Markus Heep; Rienk Pypstra; Joseph S Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

Review 4.  Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.

Authors:  Bindu Murthy; Anne Schmitt-Hoffmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.

Authors:  Karen M Amsler; Todd A Davies; Wenchi Shang; Michael R Jacobs; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

6.  A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.

Authors:  Gary J Noel; Karen Bush; Partha Bagchi; Juliana Ianus; Richard S Strauss
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

7.  Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Lars Nyman; Brigitte Roos; Michael Schleimer; Jill Sauer; Norman Nashed; Thomas Brown; Anthony Man; Erhard Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
  7 in total
  4 in total

1.  Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.

Authors:  Anouk E Muller; Anne H Schmitt-Hoffmann; Nieko Punt; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

2.  Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections.

Authors:  Holly Kimko; Xu Xu; Partha Nandy; Mahesh N Samtani; Richard S Strauss; Partha Bagchi; Gary J Noel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

3.  Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.

Authors:  April Barbour; Hartmut Derendorf
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

Review 4.  Ceftobiprole: pharmacokinetics and PK/PD profile.

Authors:  J R Azanza Perea; B Sádaba Díaz de Rada
Journal:  Rev Esp Quimioter       Date:  2019-09       Impact factor: 1.553
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.